Trial Profile
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; BI 836858 (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Decitabine (Primary) ; Dubermatinib (Primary) ; Enasidenib (Primary) ; Entospletinib (Primary) ; Gilteritinib (Primary) ; Ivosidenib (Primary) ; Pevonedistat (Primary) ; Revumenib (Primary) ; Samalizumab (Primary) ; SRA 515 (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Biomarker; Therapeutic Use
- Acronyms The Beat AML Trial
- 20 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2026.
- 20 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2026.
- 12 Dec 2023 Trial design and protocol from sub-study of the Beat AML Master Trial presented at the 65th American Society of Hematology Annual Meeting and Exposition